ILA.AX
Healthcare BiotechnologyIsland Pharmaceuticals Limited
A$0.38
+0.02 +5.48% today
Price History
Not enough data
Key Stats
Market Cap
114.00M
Avg Volume
283,677
EPS
-A$0.04
52W High
A$0.63
52W Low
A$0.31
Div. Yield
0.0%
Valuation
Forward P/E
0.30
P/B Ratio
8.19
P/S Ratio
403.06
EV/EBITDA
-9.88
EV/Revenue
357.52
Margins
Gross Margin 0.0%
Operating Margin (2240.5%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
996.0%
Return on Equity
(95.5%)
Return on Assets
(60.1%)
Liquidity & Leverage
Current Ratio
24.62
Quick Ratio
24.43
Total Cash
12.87M
Total Debt
0
About
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
www.islandpharmaceuticals.com